Successful treatment of hypertrophic osteoarthropathy by gefitinib in a case with lung adenocarcinoma
Hayashi, M.; Sekikawa, A.; Saijo, A.; Takada, W.; Yamawaki, I.; Ohkawa, S-Ichiro.
Anticancer Research 25(3c): 2435-2438
2005
ISSN/ISBN: 0250-7005 PMID: 16080471 Document Number: 588511
Hypertrophic osteoarthropathy is an important manifestation of lung carcinoma, particularly in a non-small cell manor; and hampers quality of life. Although removal of the primary tumor usually resolves this syndrome, effective treatment in patients with advanced lung carcinoma has not been established. Recently, an orally active, selective epidermal growth factor receptor tyrosine kinase (EGFR) inhibitor ("Gefitinib") provided clinical anti-tumor activity. We describe a 71-year-old male smoker with cough, who presented with clubbed fingers. A transbronchial lung biopsy (stage T2N3M1-IV) on a cavity lesion in the left lower lobe showed the features of adenocarcinoma, while bone scintigram revealed bilaterally symmetrical abnormal uptakes in the lower extremities, suggesting secondary hypertrophic osteoarthropathy. The serum level of growth hormone was increased to 1.42 ng/ml. Chemotherapy (cisplatin, vinorelbine) was not effective. Gefitinib, as a second-line therapy, induced disappearance of the abnormal accumulation on bone scintigraphy and decrease of the cavity in the lung and of serum growth hormone. The presented case suggests that the EGFR inhibitor might be a promising option for the treatment of hypertrophic osteoarthropathy with advanced lung adenocarcinoma.